Calcivis, an Edinburgh-based dental technology company, has secured £5 million in funding to bring its early detection technology for tooth decay to market. The investment round was led by £4 million from the Scottish National Investment Bank and £1 million from IFS Maven Equity Finance, managed by Maven Capital Partners.
Calcivis’ flagship product uses a biologic diagnostic to enable preventative treatment before tooth decay becomes irreversible. Founded in 2012 by CEO Adam Christie and CTO Bruce Vernon, the company plans to introduce its technology first in the US, followed by a launch in the UK and other European markets.
According to Christie, early diagnosis and treatment of tooth decay are critical to preventing irreversible damage. He expressed excitement about the potential of their technology to revolutionize prevention in oral healthcare globally, as cavities affect over two billion people worldwide according to the World Health Organization.
Investment director Paul Callaghan at the Scottish National Investment Bank highlighted Calcivis’ role in leading innovation in health technology in Scotland. He stated that the bank is proud to support the company’s growth and help expand its product into international markets, creating job opportunities in Scotland. The bank sees Calcivis’ technology as aligned with its Innovation mission and believes that the product’s launch in the UK holds significant health benefits for the people of Scotland.
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/SHZS63UVUVBIHKYXCRRMDXZQHI.jpg)
